

# Cancer Diagnostics Market Size Forecast to USD 292.4 Billion by 2035 with Rising Emphasis on Early Detection – TMR

*Rising Adoption of AI and Genomics in Cancer Diagnostics to Drive Market Beyond USD 292.4 Billion by 2035 - TMR Analysis*

WILMINGTON, DE, UNITED STATES,  
August 19, 2025 /EINPresswire.com/ --  
[Cancer Diagnostics Market](#) Outlook  
2035

The global cancer diagnostics market is set for robust expansion, driven by rising cancer prevalence, technological innovations in screening methods, and increasing adoption of precision

oncology tools. Valued at US\$ 121.8 Billion in 2024, the market is projected to grow at a CAGR of 8.4% from 2025 to 2035, crossing US\$ 292.4 Billion by the end of 2035.

Growing demand for early detection, liquid biopsy techniques, and AI-driven imaging solutions is transforming the landscape of cancer diagnostics.

Advancements in genomics, next-generation sequencing (NGS), and companion diagnostics are further fueling market expansion.

“

Cancer Diagnostics Market  
Outlook 2035 Market Size to  
Expand from USD 121.8  
Billion in 2024 to USD 292.4  
Billion”

*Trending Report by TMR*

□ Don't miss out on the latest intelligence. Get your sample report copy today @

[https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep\\_id=3637](https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3637)

## CANCER DIAGNOSTICS MARKET OUTLOOK 2035

VALUATION  
(2024)


**US\$ 121.8 Bn**

GROWTH RATE  
(CAGR 2025-2035)

**8.4%**

FORECAST VALUATION  
(2035)

**OVER  
US\$ 292.4 Bn**



The cancer diagnostics market is set to expand significantly over the next decade, fueled by rising cancer prevalence, technological innovations in early detection, and increasing demand for precision

Cancer Diagnostics Market Outlook 2035

Market Overview

Cancer diagnostics—encompassing imaging, biomarkers, molecular testing, and

histopathology—plays a pivotal role in detecting malignancies at early stages and guiding patient-specific treatment. From MRI, CT, and PET scans to genomic testing and immunohistochemistry, the integration of multimodal diagnostics is enabling more accurate and less invasive detection.

Breakthroughs such as liquid biopsy and AI-enabled digital pathology are creating new possibilities for real-time monitoring, personalized therapy selection, and improved patient outcomes.

### Analyst Viewpoint

Analysts view the cancer diagnostics market as the foundation of precision oncology. The convergence of digital health, genomics, and molecular imaging is redefining cancer care by moving from “one-size-fits-all” to patient-specific treatment pathways.

Industry experts emphasize that innovation is not limited to new tests, but also extends to workflow integration, regulatory harmonization, and AI-driven decision support tools. With healthcare systems pushing toward value-based care, cancer diagnostics will continue to evolve as a central driver of patient management and survival outcomes.

### Analysis of Key Players in the Cancer Diagnostics Market

The cancer diagnostics market is highly competitive, with major players focusing on technological innovation, strategic acquisitions, and partnerships with pharma companies to strengthen their diagnostic portfolios.

Leading companies include:

- Cancer Diagnostics, Inc.
- Abbott
- Bio-Rad Laboratories, Inc.
- GE HealthCare
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche AG
- Quest Diagnostics Incorporated
- QIAGEN
- Siemens Healthineers
- MedGenome
- Biodesix

Each company is profiled in the cancer diagnostics market research report based on company overview, financials, product pipeline, technological innovation, strategic initiatives, and partnerships.

## Key Developments

- March 2025 – VolitionRx Limited announced positive study results for its automated Nu.Q Cancer immunoassay test, which successfully detected 21 different cancers. The test demonstrates potential as a standalone pan-cancer diagnostic tool or as a complementary solution alongside other liquid biopsy technologies, thanks to its low false-positive rate in healthy individuals.
- August 2024 – Hitachi High-Tech Corporation and Gencurix, Inc. entered into a strategic partnership in cancer molecular diagnostics. The collaboration focuses on developing innovative testing services by leveraging Hitachi High-Tech's expertise in R&D and in-vitro diagnostic manufacturing, combined with Gencurix's biomarker technology and experience.

## Key Strategies by Market Players

- Liquid Biopsy Expansion  
Development of blood-based tests for early cancer detection and treatment monitoring.
- AI & Digital Pathology  
Leveraging machine learning for image analysis, tumor grading, and workflow automation.
- Strategic Collaborations  
Partnerships between diagnostic companies and pharmaceutical firms for companion diagnostics.
- Genomic & Molecular Testing  
Wider adoption of NGS panels and multi-cancer early detection tests.
- Geographic Expansion  
Investment in emerging markets such as Asia Pacific and Latin America to enhance screening access.

□ Detailed strategy mapping available in the sample report copy –

[https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep\\_id=3637](https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3637)

## Key Growth Drivers

1. Rising Global Cancer Burden  
Increasing incidence of lung, breast, colorectal, and prostate cancers is creating massive demand for early detection tools.
2. Technological Advancements in Imaging  
Hybrid imaging (PET/CT, PET/MRI) and AI-powered radiology are improving diagnostic precision.
3. Emergence of Liquid Biopsy  
Non-invasive, real-time monitoring of tumor progression through circulating tumor DNA (ctDNA).
4. Genomic Medicine & Precision Oncology  
Companion diagnostics supporting targeted therapies and immuno-oncology drugs.

## 5. Government & Private Funding

Mass screening initiatives, cancer research funding, and public-private partnerships.

## 6. Aging Population & Lifestyle Risks

Older demographics and lifestyle-related cancers are increasing demand for diagnostics.

### Market Segmentation Snapshot

- By Test Type:
  - o Imaging (MRI, CT, PET, Mammography)
  - o Biopsy & Histopathology
  - o Molecular Diagnostics (NGS, PCR, FISH)
  - o Liquid Biopsy
  - o Immunoassays & Others
- By Application:
  - o Breast Cancer
  - o Lung Cancer
  - o Colorectal Cancer
  - o Prostate Cancer
  - o Others (Liver, Cervical, Ovarian)
- By End-user:
  - o Hospitals
  - o Diagnostic Laboratories
  - o Cancer Research Institutes
  - o Specialty Clinics

### Regional Description

- North America: Dominant market due to advanced healthcare infrastructure, strong adoption of liquid biopsy, and favorable reimbursement policies.
- Europe: Rapid uptake of personalized diagnostics, strong cancer screening programs, and digital pathology adoption in Germany, UK, and France.
- Asia Pacific: Fastest-growing region, fueled by high cancer incidence, rising healthcare expenditure, and government support in China, India, and Japan.
- Latin America & Middle East: Emerging opportunities driven by increasing diagnostic imaging installations and national cancer control programs.

### Key Takeaways for Stakeholders

- For Manufacturers: Invest in multi-cancer early detection platforms and digital pathology solutions.
- For Investors: High growth potential in liquid biopsy and NGS-driven diagnostics.

- For Hospitals & Labs: Upgrade imaging, digital pathology, and genomic testing capacities.
- For Distributors: Expand supply chains to emerging economies with rising cancer prevalence.

### Why Buy This Report?

- Comprehensive analysis of cancer diagnostics technologies, applications, and market outlook
- Future-ready insights with forecasts up to 2035
- Regulatory landscape review covering FDA, EMA, and global approvals
- Growth opportunity mapping across test types and geographies

□ Purchase the full report now @

[https://www.transparencymarketresearch.com/checkout.php?rep\\_id=3637&ltype=S](https://www.transparencymarketresearch.com/checkout.php?rep_id=3637&ltype=S)

### Future Outlook: Toward Precision Cancer Care by 2035

The cancer diagnostics market will play a defining role in precision oncology and integrated patient care. Advances in molecular imaging, AI, and multi-omics profiling will empower clinicians to diagnose cancers earlier, predict therapeutic response, and personalize treatment strategies.

### Emerging Trends:

- Multi-cancer early detection (MCED) tests via blood-based platforms
- AI-driven pathology for faster, more accurate tumor classification
- Integration of genomics and proteomics for precision therapy selection
- Expansion of at-home cancer screening kits
- Adoption of decentralized diagnostics in emerging markets

### Conclusion

The cancer diagnostics market stands at the forefront of oncology transformation. With powerful tools for early detection and personalized treatment planning, diagnostics are becoming the cornerstone of cancer care. For companies, investors, and healthcare providers, this is the moment to invest, innovate, and collaborate in shaping the future of cancer management.

### More Trending Research Reports-

- Cancer Biomarkers Market - <https://www.transparencymarketresearch.com/cancer-biomarkers-market.html>
- Cancer Stem Cells Market - <https://www.transparencymarketresearch.com/cancer-stem-cells-market.html>
- Cancer Immunotherapy Market - <https://www.transparencymarketresearch.com/cancer-immunotherapy-market.html>
- Cancer Cachexia Market - <https://www.transparencymarketresearch.com/cancer-cachexia->

[market.html](#)

- Cancer Profiling Market - <https://www.transparencymarketresearch.com/cancer-profiling-market.html>
- Cancer Biologics Market - <https://www.transparencymarketresearch.com/cancer-biologics-market.html>
- Cancer Biopsy Market - <https://www.transparencymarketresearch.com/cancer-biopsy-market.html>
- Cancer Supportive Care Drugs Market - <https://www.transparencymarketresearch.com/cancer-supportive-care-drugs-market.html>
- Cancer Vaccines Market - <https://www.transparencymarketresearch.com/cancer-vaccines-market-report.html>
- Non-Invasive Cancer Diagnostics Market - <https://www.transparencymarketresearch.com/noninvasive-cancer-diagnostics-market.html>
- Lung Cancer Diagnostics Market - <https://www.transparencymarketresearch.com/lung-cancer-diagnostics-market.html>
- Breast Cancer Diagnostics Market - <https://www.transparencymarketresearch.com/breast-cancer-diagnostics-market.html>
- Kidney Cancer Diagnostics Market - <https://www.transparencymarketresearch.com/kidney-cancer-diagnostics-market.html>
- AI in Cancer Diagnostics Market - <https://www.transparencymarketresearch.com/ai-in-cancer-diagnostics-market.html>
- Brain Cancer Diagnostics Market - <https://www.transparencymarketresearch.com/brain-cancer-diagnostics-market.html>

## About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

## Contact Us

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,  
1000 N. West Street,  
Suite 1200, Wilmington, Delaware 19801 USA  
Tel: +1-518-618-1030  
USA - Canada Toll Free: 866-552-3453  
Website: <https://www.transparencymarketresearch.com>  
Blog: <https://tmrblog.com>  
Email: [sales@transparencymarketresearch.com](mailto:sales@transparencymarketresearch.com)

Atil Chaudhari  
Transparency Market Research Inc.  
+ +1 518-618-1030  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/841176517>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.